Naveed Siddiqi

Naveed Siddiqi, M.D., has served as a member of the board of directors since June 2021. Dr. Siddiqi brings more than 22 years of experience in life science venture investments and investment banking. Since 2019, he has been employed as a Senior Partner at Novo Holdings A/S, a Danish limited liability company that manages over $13 billion of life science investment assets. As part of the Novo Ventures team, he has been involved in both private, public and limited partner investments. From December 2013 to December 2018, Dr. Siddiqi was a Partner at Andera Partners, a venture capital and growth equity firm based in Paris, focusing on science investments in Europe and the United States. Prior to joining Andera Partners, Dr. Siddiqi worked in London for Nomura Phase4 Ventures, Nomura International, EFG Corporate Finance, KPMG, and as a medical doctor in the United Kingdom National Health Service. Throughout his career, he has served on the board of directors of a number of private life science companies in both the United States and Europe, several of which successfully listed on NASDAQ. In addition to ReViral, he currently serves on the boards of Amolyt Pharma SAS, F2G Limited, and the LP advisory committee of Biogeneration Ventures.

Dr. Siddiqi obtained his M.D. from Guy’s and St. Thomas’ Hospital Medical School (now King’s College London) and later qualified as a Chartered Accountant from the Institute of Chartered Accountants England & Wales.